Dark

EDIT
Editas Medicine, Inc. Common Stock
stock NASDAQ

At Close

May 16, 2025 3:59:30 PM EDT

1.51USD+8.244%(+0.12)1,611,949

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 16, 2025 8:59:30 AM EDT

1.43USD+2.452%(+0.03)23,855

After-hours

May 16, 2025 4:47:30 PM EDT

1.50USD-0.662%(-0.01)71,119

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

07:00AM EST Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 GlobeNewswire Inc

Jan 6, 2022

10:32AM EST Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $24 Benzinga

Jan 4, 2022

06:58AM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET GlobeNewswire Inc

Dec 20, 2021

08:32AM EST Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights Board of Directors as an independent director, effective December 15, 2021. GlobeNewswire Inc

07:07AM EST Editas Medicine: FDA Clears IND Application For EDIT-301 For Transfusion-Dependent Beta Thalassemia RTTNews

07:05AM EST Editas Medicine to Initaite a Phase 1/2 Clinical Study of EDIT-301 Following FDA Clearance of its Investigational New Druga Application Benzinga

07:00AM EST EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia GlobeNewswire Inc

Dec 14, 2021

02:51PM EST CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine' Benzinga

Dec 13, 2021

12:56PM EST Editas Medicine Late Sunday Announced Preclinical Data Showed Tumor Reduction, Clearance Using Novel, Engineered Induced Pluriopotent Stem Cell-Derived Natural Killer Cells At American Society Of Hematology Meeting Benzinga

Dec 12, 2021

06:00PM EST Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors GlobeNewswire Inc

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST Editas Medicine Presents Preclinical Data on Novel Engineered GlobeNewswire Inc

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

07:05AM EST Editas Medicine Q3 EPS $(0.57) Beats $(0.82) Estimate, Sales $6.20M Beat $4.78M Estimate Benzinga

07:00AM EST EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 4, 2021

09:24AM EDT Editas Medicine To Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines For The Treatment Of Hemoglobinopathies And Cancer At The ASH Annual Meeting And Exposition Benzinga

Oct 28, 2021

09:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors. GlobeNewswire Inc

Oct 25, 2021

04:01PM EDT Editas Medicine, Inc.(Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast onMonday, November 8, 2021, at8:00 a.m. ETto provide a corporate update and results for the third quarter of 2021. GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

Oct 20, 2021

09:03AM EDT Editas Medicine Says Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10 To Be Presented At European Society Of Gene And Cell Therapy Annual Congress Benzinga

09:00AM EDT Clinical Data from Editas Medicines Ongoing GlobeNewswire Inc

Oct 19, 2021

12:07PM EDT Analyst Ratings For Editas Medicine Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 Benzinga

06:21AM EDT SVB Leerink Initiates Coverage On Editas Medicine with Market Perform Rating, Announces Price Target of $41 Benzinga

Oct 7, 2021

08:10AM EDT Editas Medicine To Present Preclinical Data On Novel Engineered iPSC Derived NK Cells For The Treatment Of Cancer At The Society For Immunotherapy Of Cancer 36Th Annual Meeting Benzinga

08:05AM EDT Editas Medicine To Present Preclinical Data On Novel Engineered iPSC Derived NK Cells For Treatment Of Cancer At Society For Immunotherapy Of Cancer 36th Annual Meeting Benzinga

08:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021. GlobeNewswire Inc

Sep 30, 2021

08:16AM EDT Editas Medicine To Present At Chardan's 5th Annual Genetic Medicines Conference Oct. 4 Benzinga

08:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardans 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET. GlobeNewswire Inc

Sep 29, 2021

10:58AM EDT Shares of genome editing company Editas Medicine, Inc. (EDIT) are down 13 percent on Wednesday's trading despite the company announcing positive initial clinical data from its ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101. RTTNews

09:12AM EDT Editas Medicine Announces Initial Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10 Benzinga

09:00AM EDT No serious adverse events or dose-limiting toxicities observed to date GlobeNewswire Inc

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

06:11AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 6.00 A.M. EDT). RTTNews

Sep 24, 2021

10:43AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 Benzinga

05:20AM EDT Stifel Initiates Coverage On Editas Medicine with Hold Rating, Announces Price Target of $65 Benzinga

Sep 13, 2021

08:00AM EDT Aadi Bioscience Appoints Emma Reeve to its Board of Directors GlobeNewswire Inc

Sep 10, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 Benzinga

08:29AM EDT 10 Biggest Price Target Changes For Friday Benzinga

05:00AM EDT Oppenheimer Upgrades Editas Medicine to Outperform, Raises Price Target to $80 Benzinga

Sep 8, 2021

09:00AM EDT Editas Medicine, Inc. (NASDAQ: EDIT), a leadinggenome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. GlobeNewswire Inc

Sep 7, 2021

04:01PM EDT Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September Benzinga

04:00PM EDT Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity GlobeNewswire Inc

Sep 2, 2021

08:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 20, 2021

04:20PM EDT SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells GlobeNewswire Inc

Aug 9, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 Benzinga

07:53AM EDT Truist Securities Upgrades Editas Medicine to Buy, Raises Price Target to $80 Benzinga

Aug 5, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 Benzinga

08:10AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

05:19AM EDT Evercore ISI Group Upgrades Editas Medicine to Outperform, Raises Price Target to $60 Benzinga

Aug 4, 2021

07:18AM EDT Editas Medicine Q2 EPS $(0.81) Beats $(0.83) Estimate, Sales $400.00K Miss $6.17M Estimate Benzinga

07:00AM EDT Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10 GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Jul 29, 2021

09:08AM EDT Editas Medicine And IDT Highlight Publication In Nature Communications Of Research Data Supporting Use Of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, In Researching Potential Of Gene-Edited Cell Medicines Benzinga

09:00AM EDT Editas Medicine and IDT Announce Publication in Nature GlobeNewswire Inc

Jul 28, 2021

07:00AM EDT Editas Medicine, Inc.(Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast onWednesday, August 4, 2021, at8:00 a.m. ETto provide a corporate update and results for the second quarter of 2021. GlobeNewswire Inc

Jul 26, 2021

09:00AM EDT Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role GlobeNewswire Inc

Jul 21, 2021

11:49AM EDT Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next? Benzinga

Jul 12, 2021

03:12PM EDT WHO Issues Framework For Governance For Gene Editing Technologies Benzinga

Jun 28, 2021

03:53PM EDT EDIT Editas Medicine Option Alert: Jul 16 $60 Calls at the Ask: 600 @ $0.95 vs 0 OI; Earnings 8/5 After Close [est] Ref=$43.735 Benzinga

10:05AM EDT Shares of Editas Medicine Inc. (EDIT) are currently trading at $46.10, up $4.22 or 10.08%, with trading volume soaring over 2.47 million versus an average volume of 1.26 million shares. The stock has been trading between $27.01 and $99.95 for the past one year. RTTNews

Jun 23, 2021

07:00AM EDT Editas Medicine Announces Enrollment Of First Pediatric Cohort In BRILLIANCE Clinical Trial of EDIT-101 For Treatment Of LCA10 Following IDMC Endorsement Benzinga

07:00AM EDT IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts GlobeNewswire Inc

Jun 15, 2021

04:01PM EDT Editas Medicine Reports Inducement Grants to New Chief Scientific GlobeNewswire Inc

Jun 14, 2021

09:00AM EDT Editas Medicine Strengthens Executive Leadership Team to Advance GlobeNewswire Inc

Jun 11, 2021

06:01AM EDT Editas Medicine Highlights Presentation Of Preclinical Data Supporting Initiation Of EDIT-301 Phase 1/2 RUBY Trial For Treatment Of Sickle Cell Disease At European Hematology Association Congress Benzinga

06:00AM EDT Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior GlobeNewswire Inc

Jun 9, 2021

10:44AM EDT Editas Medicine Option Alert: Jul 16 $45 Calls Sweep (5) near the Ask: 270 @ $1.95 vs 1134 OI; Earnings 8/5 After Close [est] Ref=$37.97 Benzinga

May 10, 2021

08:59AM EDT Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $37 Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:30AM EDT Editas Medicine Q1 EPS $(0.86) Misses $(0.75) Estimate Benzinga

07:00AM EDT Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer GlobeNewswire Inc

06:59AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Companys Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Companys pipeline of experimental medicines. GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga

09:08AM EDT Editas Medicine Reports Will Present Preclinical Data Showing Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting May 10, 11 Benzinga

09:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held virtually May 11 14, 2021. GlobeNewswire Inc

06:30AM EDT RBC Capital Initiates Coverage On Editas Medicine with Sector Perform Rating, Announces Price Target of $40 Benzinga

May 1, 2021

07:12AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO)Annual Meeting being held virtually May 1 7, 2021. The Company is presenting preclinical data on its Usher Syndrome2A(USH2A) andretinitis pigmentosa4(RP4) programs. GlobeNewswire Inc

Apr 28, 2021

07:01AM EDT Editas Medicine, Inc.(Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast onWednesday, May 5, 2021, at8:00 a.m. ETto discuss a corporate update and results for the first quarter of 2021. GlobeNewswire Inc

Apr 16, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 Benzinga

06:11AM EDT Goldman Sachs Initiates Coverage On Editas Medicine with Sell Rating, Announces Price Target of $20 Benzinga

Mar 22, 2021

10:43AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2021 Benzinga

07:28AM EDT Credit Suisse Initiates Coverage On Editas Medicine with Outperform Rating, Announces Price Target of $58 Benzinga

Mar 6, 2021

01:14PM EST The Past Week's Most Notable Insider Buys: Editas, Exxon Mobil, Wayfare And More Benzinga

Mar 2, 2021

08:01AM EST Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $40 Benzinga

Mar 1, 2021

04:40PM EST Editas Medicine Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed Benzinga

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga

08:00AM EST Barclays Downgrades Editas Medicine to Equal-Weight, Announces $46 Price Target Benzinga

Feb 26, 2021

10:50AM EST Truist Securities Downgrades Editas Medicine to Hold, Announces $45 Price Target Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:24AM EST Editas Medicine Q4 EPS $(1.00) Misses $(0.74) Estimate, Sales $11.42M Beat $5.64M Estimate Benzinga

07:00AM EST Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 18, 2021

04:02PM EST Editas Medicine, Inc.(Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast onThursday, February 25, 2021, at8:00 a.m. ETto discuss a corporate update and results for the fourth quarter and full year of 2020. GlobeNewswire Inc

Feb 10, 2021

10:05AM EST Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $77 Benzinga

Feb 8, 2021

08:07AM EST Editas Medicine Appoints James Mullen As CEO RTTNews

08:06AM EST Editas Medicine Announces James Mullen CEO Benzinga

08:00AM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of the Companys Board of Directors. GlobeNewswire Inc

Jan 21, 2021

05:35AM EST Editas Medicine Priced 3.5M Share Offering of Common Stock @$66/Share Benzinga

Jan 20, 2021

10:56PM EST Editas Medicine Prices Public Offering Of 3.5 Mln Shares At $66/Shr RTTNews

10:30PM EST Editas Medicine Announces Pricing of Offering of Common Stock GlobeNewswire Inc

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

04:03PM EST Editas Medicine Announces Offering of 3.5M Shares of Common Stock Benzinga

04:01PM EST Editas Medicine Announces Offering of Common Stock GlobeNewswire Inc

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2021 Benzinga

06:32AM EST Morgan Stanley Downgrades Editas Medicine to Underweight, Lowers Price Target to $45 Benzinga

Jan 11, 2021

11:28AM EST Editas Medicine Chief Scientific Officer Resigns to Pursue Another Opportunity Benzinga

06:11AM EST Editas Medicine Says Chief Scientific Officer Charles Albright Is Stepping Down On January 15 RTTNews

06:10AM EST Editas Medicine Announces CFO Charles Albright Will Be Stepping Down Benzinga

06:09AM EST Editas Says FDA Cleared Initiation Of Safety Phase Of EDIT-301 Clinical Trial RTTNews

06:09AM EST Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial Benzinga

06:05AM EST Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates GlobeNewswire Inc

06:02AM EST Editas Medicine Announces the FDA has Cleared Initiation of the GlobeNewswire Inc

06:00AM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright. GlobeNewswire Inc

Jan 8, 2021

10:57AM EST Raymond James Downgrades Editas Medicine to Market Perform Benzinga

Jan 4, 2021

04:05PM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET. GlobeNewswire Inc

Dec 22, 2020

09:58AM EST Return On Capital Employed Overview: Editas Medicine Benzinga

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 17, 2020

04:05PM EST Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. GlobeNewswire Inc

Dec 16, 2020

12:33PM EST Morgan Stanley Maintains Equal-Weight on Editas Medicine, Raises Price Target to $64 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

09:51AM EST Shares of genome editing company Editas Medicine, Inc. (EDIT) are climbing more than 16 percent or $8.27 in Thursday's morning trade at $58.85, after hitting a new 52-week high of $60.48. RTTNews

09:44AM EST Looking Into Editas Medicine's Return On Capital Employed Benzinga

07:55AM EST 10 Biggest Price Target Changes For Thursday Benzinga

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

05:45AM EST Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $69 Benzinga

Dec 9, 2020

04:03PM EST Editas Medicine Reports Submission Of Investigational New Drug Application For EDIT-301 For Sickle Cell Benzinga

04:01PM EST EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease GlobeNewswire Inc

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 5, 2020

10:00AM EST Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies GlobeNewswire Inc

Nov 11, 2020

07:57AM EST Morgan Stanley Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $30 Benzinga

Nov 10, 2020

04:01PM EST Editas Medicine Reports Inducement Grants to New Chief Medical Officer GlobeNewswire Inc

Nov 9, 2020

04:05PM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET. GlobeNewswire Inc

09:00AM EST Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Companys Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead clinical research and drug development for the Companys pipeline of experimental medicines. GlobeNewswire Inc

Nov 6, 2020

09:36AM EST Raymond James Maintains Outperform on Editas Medicine, Lowers Price Target to $60 Benzinga

Nov 5, 2020

04:10PM EST Editas Medicine Q3 EPS $0.12 May Not Compare To $(0.61) Estimate, Sales $62.84M May Not Compare To $6.36M Estimate Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 3, 2020

09:33AM EST Benzinga's Top Upgrades, Downgrades For November 3, 2020 Benzinga

07:18AM EST Baird Initiates Coverage On Editas Medicine with Underperform Rating, Announces Price Target of $14 Benzinga

Oct 13, 2020

08:50AM EDT Morgan Stanley Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $31 Benzinga

Oct 8, 2020

08:16AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Oct. 8, 2020: TSLA, JNJ, ROKU, IH, EDIT Benzinga

Oct 1, 2020

08:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference: GlobeNewswire Inc

Sep 11, 2020

07:01AM EDT Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference Benzinga

07:00AM EDT Editas Medicine Announces U.S. Patent and Trademark Office Grants GlobeNewswire Inc

Sep 4, 2020

08:00AM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 24, 2020

08:38AM EDT Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For Treatment Of Sickle Cell Disease Benzinga

08:30AM EDT Editas Medicine Receives Rare Pediatric Disease Designation for GlobeNewswire Inc

Aug 10, 2020

09:04AM EDT Morgan Stanley Maintains Equal-Weight on Editas Medicine, Raises Price Target to $32 Benzinga

Aug 7, 2020

07:40AM EDT Raymond James Maintains Outperform on Editas Medicine, Raises Price Target to $65 Benzinga

Aug 6, 2020

05:17PM EDT Editas Medicine Q2 EPS $(0.43) Beats $(0.79) Estimate, Sales $10.75M Beat $6.34M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 3, 2020

10:39AM EDT Editas Medicine Option Alert: Aug 21 $45 Calls at the Ask: 1171 @ $0.3 vs 11933 OI; Earnings 8/6 After Close Ref=$30.4135 Benzinga

Jul 29, 2020

08:07AM EDT Catalent Enters Into Strategic Partnership With Editas Medicine To Support Gene Editing Medicine Pipeline Benzinga

08:00AM EDT Catalent Enters into Strategic Partnership with Editas Medicine to GlobeNewswire Inc

Jul 27, 2020

04:01PM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has named Gad Berdugo as the Companys Chief Business Officer. Mr. Berdugo will oversee the Companys business and corporate development, alliance management, and strategy initiatives. GlobeNewswire Inc

Jul 23, 2020

04:01PM EDT Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, August 6, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of 2020. GlobeNewswire Inc